Clarient, A GE Healthcare Company, Introduces First Lab Developed Test To Assess Multiple Proteins at Single-Cell Level

  Clarient, A GE Healthcare Company, Introduces First Lab Developed Test To
  Assess Multiple Proteins at Single-Cell Level

  *MultiOmyx™ technology aids in pathologist’s diagnosis of certain difficult
    lymphoma cases by doing more with less tissue
  *May provide a more complete picture of a patient’s cancer and help explain
    tumor behavior and growth
  *Paper in Proceedings of the National Academy of Sciences affirms relevance
    of GE’s MultiOmyx™ molecular pathology tumor analysis

Business Wire

ALISO VIEJO, Calif. -- July 10, 2013

GE Healthcare today announced the introduction by Clarient Diagnostic
Services, a GE Healthcare Company, of the first lab developed test using
MultiOmyx^™, a ground-breaking new pathology platform which uses proprietary
methodology to assess multiple proteins from a single tissue section at a
single-cell level. This test, now available, offers an aid to a pathologist’s
diagnosis of CD30-positive lymphoma cases with difficult morphology or
otherwise insufficient tissue to adequately evaluate the case.

“In many instances, suspected lymphoma cases are not straightforward, and
sample tissue size inadequacy issues further complicate the matter,” said
Lawrence Weiss, MD, Medical Director of Clarient.“In difficult to call
diagnoses, MultiOmyx gives me great confidence in making the diagnosis and
relieves me from the concern of running out of tissue. If I only have a small
amount of tissue, I do not have to sacrifice or choose between important
markers – I can assess them all.”

The Hodgkin Lymphoma (HL) Profile by MultiOmyx helps to assess nine unique
antibodies (CD30, CD15, CD20, CD45, PAX5, OCT2, BOB1, CD3, and CD79A) on a
single formalin fixed paraffin embedded tissue section to aid in differential
diagnosis of Classical HL.

In clinical validation, this single slide assay called the Hodgkin Lymphoma
Profile by MultiOmyx demonstrated high levels of accuracy, diagnostic
reproducibility and repeatability, and high sensitivity of all
immunofluorescent stains in comparison to traditional immunohistochemistry
performed on the same samples. The correlation study identified unique cases
where MultiOmyx demonstrated improved performance.

“Traditional pathology uses multiple slices from paraffin-fixed tumor samples
and examines them slide by slide, which is less efficient and effective,”
saidCarrie Eglinton Manner, CEO, Clarient. “Using a single slide may save
time, uses significantly less tissue and may provide a more consistent result.
Since different parts of a tumor sample can act differently and because less
tissue is required, pathologists can access the most accurate and broad tumor
analysis available, while eliminating today’s need to prioritize tests due to
limited tissue availability.”

The relevance of the MultiOmyx technology was recently confirmed in a clinical
paper written by a team of scientists from GE Global Research published in
Proceedings of the National Academy of Sciences (PNAS). The paper details the
different ways GE is using image data to visualize cancer and the relationship
between different biomarkers and the tumor environment and suggests the
technology could be broadly applicable to problems in basic biological
research, drug discovery and development and companion and clinical
diagnostics.

“MultiOmyx ^ provides clinicians and researchers with a novel biomarker
multiplexing method to understand biological context in a way that is not
possible with other technologies that disrupt the tissue histology. Once cells
are removed from the context of their overall microenvironment with other
methods valuable information is lost,” said Christine Kuslich, PhD, Chief
Science Officer, In Vitro Diagnostics, GE Life Sciences. “MultiOmyx uniquely
facilitates the ability to visualize multiple biological pathways, local
immune response as well as heterogeneity of expression within regions of
interest on a cell-by-cell basis from a single tissue section maintaining
tissue context.”

The platform uses fluorescence to provide quantitative analysis of antibodies
and allows for up to 60 proteins to be examined on a single tissue sample. It
creates a “digital map” of the tumor, giving each cell an “address” and
allowing for a clear graphic representation of protein expression. Matching
this map to known biosignatures gives researchers a more accurate
representation of the exact characteristics of the tumor and may provide
clinicians with a clearer view to aid the diagnosis. It also allows them to
identify patterns in the tissue by analyzing each cell and biomarker
individually, or as a cluster, and thus get a level of understanding of the
biological process that could not be achieved via traditional methods.

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to
meet the demand for increased access, enhanced quality and more affordable
healthcare around the world. GE (NYSE: GE) works on things that matter - great
people and technologies taking on tough challenges. From medical imaging,
software & IT, patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance improvement
solutions, GE Healthcare helps medical professionals deliver great healthcare
to their patients.

For our latest news, please visit http://newsroom.gehealthcare.com

About Clarient Diagnostic Services, Inc.

Clarient Diagnostic Services, Inc. is CLIA and NYS licensed, CAP accredited
and a leading provider of comprehensive, cancer–diagnostic laboratory
services. With its advanced technologies, Clarient is able to provide
pathologists and oncologist with more accurate and detailed information to
better characterize and assess cancer which can lead to more accurate
diagnoses and more effective treatment. In addition, Clarient’s services are
finding more efficient ways to reduce the cost as well as accelerating the
drug development process to identify and develop treating pharmaceuticals that
can result in better outcomes for patients.

From its state-of-the-art diagnostic laboratory to its Internet-based
PATHSiTE^®, Clarient delivers advanced oncology diagnostic services to
pathologists, oncologists, hospitals and biopharmaceutical companies
throughout the U.S. Clarient also is developing tests for therapeutics in
breast, prostate, lung and colon cancers, as well as leukemia/lymphoma.

Clarient is improving the lives of those affected by cancer by bringing
clarity to a complex disease. For more information visit www.clarientinc.com.

About GE Global Research

GE Global Research is the hub of technology development for all of GE's
businesses. Our scientists and engineers redefine what’s possible, drive
growth for our businesses, and find answers to some of the world’s toughest
problems.

We innovate 24 hours a day, with sites in Niskayuna, New York; San Ramon,
California; Bangalore, India; Shanghai, China; Munich, Germany; and Rio de
Janeiro, Brazil.

Visit GE Global Research on the web at www.ge.com/research. Connect with our
technologists at http://edisonsdesk.com and http://twitter.com/edisonsdesk.

Photos/Multimedia Gallery Available:
http://www.businesswire.com/multimedia/home/20130710005483/en/

Multimedia
Available:http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50667226&lang=en

Contact:

Media:
GE Healthcare
Aleisia Gibson, 609-514-6046
201-289-3832 (mobile)
aleisia.gibson@ge.com
or
Scott Lerman, 609-514-6346
609-937-9253 (mobile)
scott.lerman@ge.com